Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic inflammatory demyelinating polyneuropathy.

Richard A Lewis1

  • 1Wayne State School of Medicine, 8-D University Health Center, 4201 St. Antoine, Detroit, MI 48201, USA. rlewis@med.wayne.edu

Neurologic Clinics
|February 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Austin Sumner 1938-2025.

Neurology·2026
Same author

Corrigendum to 'Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20' [Journal of the Neurological Sciences, 486 (2026) 125918].

Journal of the neurological sciences·2026
Same author

Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20.

Journal of the neurological sciences·2026
Same author

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial.

Therapeutic advances in neurological disorders·2026
Same author

Expanding the Clinical and Molecular Spectrum of <i>TUBB2B</i> Through Distinct Variants Identified Across Multiple Families.

medRxiv : the preprint server for health sciences·2026
Same author

CEP76 impairment at the centrosome-cilium interface contributes to a spectrum of ciliopathies.

Science advances·2025
Same journal

Sports Neurology.

Neurologic clinics·2026
Same journal

Sports-Related Peripheral Nerve Injuries.

Neurologic clinics·2026
Same journal

Active Rehabilitation and Return to Play in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Autonomic Assessment and Management in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Management of Vestibular Symptoms in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Neuropsychological Assessment in Sport-Related Concussion: Evidence, Controversies, and Clinical Applications.

Neurologic clinics·2026
See all related articles

Chronic inflammatory demyelinating polyneuropathy (CIDP) is defined by demyelination. Recognizing distinct variants and associated disorders is crucial for accurate diagnosis and treatment decisions in immune-mediated neuropathies.

Area of Science:

  • Neurology
  • Immunology
  • Pathology

Background:

  • Chronic inflammatory demyelinating polyneuropathy (CIDP) was initially defined in 1975.
  • Demyelination is a key pathological feature of CIDP.
  • Over three decades, variants and associated systemic disorders have been identified.

Purpose of the Study:

  • To discuss the definition and classification of CIDP and related chronic, acquired, immune-mediated, demyelinating disorders.
  • To highlight the importance of distinguishing CIDP variants from distinct conditions.
  • To aid clinicians in making appropriate treatment decisions.

Main Methods:

  • Review of clinical, electrodiagnostic, and pathological features.
  • Analysis of literature on CIDP variants and associated systemic disorders.

Related Experiment Videos

  • Comparison of diagnostic criteria and characteristic features.

    • Main Results:

    • CIDP is characterized by demyelination.
    • Several disorders previously considered CIDP variants now possess distinct features.
    • Accurate differentiation of these conditions is possible.

    Conclusions:

    • Understanding the nuances between CIDP and its related disorders is essential for effective clinical management.
    • Recognizing distinct features aids in precise diagnosis.
    • This distinction impacts treatment strategies for immune-mediated demyelinating neuropathies.